


NIIM Prostate Cancer Screening Test



The ISET®-CTC Test

ISET® (Isolation by Size of Epithelial Tumour cells) - CTC (Circulating Tumour Cells) is a blood test that may be helpful:

- for the early detection of cancer risk
- for assessment of patients with cancer
- for the metastatic potential of cancer
- for monitoring cancer therapy (treatment efficacy)

Recent studies indicate that the CTC count (number of CTCs per ml of blood) and morphology (type of CTC: single cell or clusters) can correspond to the potential risk of malignancy and possibly the stage of the cancer. Generally, the higher the CTC count, the higher the risk.



The ISET®-CTC test uses cytopathology (microscopy) to distinguish between benign and malignant CTC, atypical cells, inflammation, pathogenic organisms and other rare cells.

NIIM is the first institute in Australia to have the ISET®-CTC technology available by Rarecells France. www.rarecells.com



To take the Prostate Cancer Screening Test

A doctor's referral is required to book in for the Prostate Cancer Screening Test. Please contact research@niim.com.au for the request form or book an appointment with a NIIM Integrative General Practitioner.

NIIM Clinic

Our clinic in Hawthorn provides an exemplary team of integrative general practitioners, allied and complementary health practitioners. Our clinicians utilise innovative therapies together with the latest in screening and treatment tools, for the ultimate in healthcare. Practitioner profiles, including professional background and special interests and information on all services can be viewed online at:



NIIM conducts the ISET®-CTC test as part of a clinical study. This study has been approved by a NHMRC registered ethics committee, and is registered on the Australian New Zealand Clinical Trials Registry.



- L3, 11-23 Burwood Road, Hawthorn VIC 3122
- niim.com.au
- (03) 9804 0646
- research@niim.com.au

Improved screening for prostate cancer using Circulating Tumour Cells (ISET®-CTC) via a simple blood test.

NIIM has developed a new blood test shown to markedly improve the early detection of prostate cancer.

The NIIM Prostate Cancer Screening Test combines the ISET®-Circulating Tumour Cells (CTC) Test with Prostate Specific Antigen (PSA) marker testing achieving more than 97% accuracy. It has a 99% accuracy of detecting true positives, and 97% accuracy of detecting true negatives. This is in contrast to the less accurate standard PSA-blood-test, which provides an accuracy of 25% true positives and 15% of true negatives.

The test is being conducted as part of an ongoing study by the NIIM Research team. The study is registered on the Australian New Zealand Clinical Trial Registry as an observational study, and has been approved by an NHMRC-registered ethics committee.


The new test protocol has been published in the peer-reviewed journal, Frontiers in Oncology, in 2020*. The new and improved prostate cancer screening test was also discussed on national TV on ABC News in July 2020.

Standard Test PSA Blood Test		New NIIM Test ISET-CTC & PSA Marker	
True Positives	True Negatives	True Positives	True Negatives
25%	14.5%	99%	97%
False Positives	False Negatives	False Positives	False Negatives
75%	85.5%	1%	3%

*Ried K, Tamanna T, Matthews S, Eng P, & Sali A (2020). New screening test improves detection of prostate cancer using circulating tumor cells and prostate-specific markers. Frontiers in Oncology, 10, 582.

The ISET®-CTC test

- The ISET®-CTC Test is a screening test not a diagnostic test
- CTCs are Circulating Tumour Cells in the blood
- CTCs are well-established biomarkers which can potentially assist with early cancer detection and assessment of treatment effectiveness
- The 'CTC count' indicates the potential risk of malignancy and possibly the stage of cancer
- The 'Isolation by SizE of Tumour (ISET®) CTC' test uses filtration and standard cytological microscopy, validated in more than 80+ peer-reviewed articles over the last 20 years. Articles can be downloaded at: <https://www.rarecells.com/iset-publications-in-oncology>.
- As of Aug 2024, NIIM has conducted over 4,200 CTC tests.



What does the CTC screening test involve?

1. A doctor's referral is required to book the ISET®-CTC blood test screening for prostate cancer.
2. 50-75 year old males may consider undertaking this test.
3. Contact: research@niim.com.au for the CTC test request form.
4. The blood tests can be done at NIIM or your local pathology lab. There is no need to fast for this blood test.
5. For interstate patients, please request a test kit, which includes blood tubes, packaging material, and a courier return envelope.
6. Your blood will be analysed locally at NIIM's research facility in Hawthorn, VIC.
7. The CTC report will be sent to your referring doctor to discuss with you. The turn-around time is usually 2 weeks.
8. The CTC test is not a standalone diagnostic test, and should be interpreted together with other clinical patient data.